Expression of Egfl7 correlates with low-grade invasive lesions in human breast cancer

Philippin-Lauridant, Géraldine; Baranzelli, Marie-Christine; Samson, Chantal; Fournier, Charles; Pinte, Sébastien; Mattot, Virginie; Bonneterre, Jacques; Soncin, Fabrice

doi:10.3892/ijo.2013.1820

Cited by 20 publications

(18 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…is involved in the pathology of certain solid tumors, including breast cancer (7), epithelial ovarian cancer (8), hepatocellular carcinoma (9), colorectal cancer (10), acute myeloid leukemia (11), and malignant glioma (12,13), However, evidence regarding the role of EGFL7 in OS is still sparse (14,20). This study had two main findings.…”

Section: Discussionmentioning

confidence: 85%

Novel Expression of EGFL7 in Osteosarcoma and Sensitivity to Cisplatin

Liu

Yuan

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Epidermal growth factor-like domain 7 (EGFL7) is a protein specifically secreted by blood vessel endothelial cells, which plays an important role in angiogenesis. Considering the aberrant secretion of EGFL7 in osteosarcoma (OS) has not yet been elucidated, this study investigated the secretion of EGFL7 in OS and the changes in its secretion after chemotherapy. We observed increased varying secretion of EGFL7 in OS tissues compared with chondrosarcoma (CS) tissues. OS cell lines and HUVECs showed higher EGFL7 mRNA and protein expression than SW1353, with OS cells expressing the highest levels. In patient samples, EGFL7 was highly expressed in the cytoplasm of OS tumor cells and vascular endothelium cells. This overexpression was abolished in OS cell and tumor tissues when treated with chemotherapy. This study is a pioneering study to investigate EGFL7 expression and localization in human OS tissues and cell. Overexpression of EGFL-7 in response to chemotherapy suggests that it can be used as a therapeutic target for OS.

show abstract

Section: Discussionmentioning

confidence: 85%

Novel Expression of EGFL7 in Osteosarcoma and Sensitivity to Cisplatin

Liu

Yuan

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…EGFL7-expression levels were found to correlate with a higher tumor grade in gliomas [23] and colon cancer [24], not in uencing the prognosis. However, it conferred poorer prognosis and higher metastatic score in hepatocellular carcinoma [25], but better prognosis and absence of lymph node invasion in human breast cancer [26]. These ambiguous results indicate that EGFL7 expression in human cancer needs to be carefully analyzed as EGFL7 may play a complex role in cancer biology depending on cancer origin [23][24][25][26] and the source of EGFL7 secretion: cancer cells, endothelium or both.…”

Section: Discussionmentioning

confidence: 99%

Activation of EGFL7 within High Grade Ovarian Serous Carcinoma is Associated with Lower Tumor Infiltrating CD4+ and CD8+ Lymphocytes

Sznurkowski

Żawrocki²,

Krawczyńska

et al. 2020

Preprint

View full text Add to dashboard Cite

It has been suggested that Epidermal Growth Factor like domain 7 (EFFL7) promotes tumor cell escape from immunity by downregulating the activation of tumor blood vessels. Aim: to analyze mRNA expression of EGFL7 within tumor microenvironment of high-grade ovarian serous carcinoma and its association with number of intraepithelial CD4+/CD8 + lymphocytes and expression of molecule involved in diapedesis ICAM-1.Methods: qPCR analysis of EGFL7 mRNA in cancer cells and adjacent stromal endothelium microdissected from formalin-fixed paraffin-embedded tumors of 59 high-grade ovarian serous carcinoma patients, was performed. Infiltration of intraepithelial lymphocytes (CD4+/CD8+) and expression of ICAM-1 were evaluated by immunohistochemistry and compared between tumors with different status of EGFL7 expression. Results: EGFL7 was expressed in cancer cells (9/59, 15.25%), endothelium (8/59, 13.56%), or both cancer cells and adjacent endothelium (4/59, 6.78%). ICAM-1 was expressed on cancer cells (47/59, 79.66%), stromal endothelium (46/59, 77.97%), or both epithelium and endothelium (40 of 59, 67.8%). EGFL7-positivity of cancer cells and endothelium was associated with lower intraepithelial inflow of CD4+ (p = 0.022 and p = 0.029, respectively) and CD8 + lymphocytes (p = 0.04 and p = 0.031, respectively) but impact neither epithelial nor endothelial ICAM-1 expression (p = 0.098 and p = 0.119, respectively). Patients' median follow-up was 23.83 months (range 1.07-78.07). Lack of prognostic significance of EGFL7-status and ICAM-1 expression was notified. Conclusion: EGFL7 was independently activated in the cancer epithelium as frequently as in endothelium of human high-grade ovarian serous carcinoma. Activation of EGFL7 on cancer cells and/or endothelium impairs influx of immune cell effectors into cancer nest.

show abstract

“…Particularly, the expression of Egfl7 is dramatically higher in invasive ductal carcinoma. 264 A recent study investigated the Egfl7 expression in normal human tissues and ten different tumors including prostate cancer. The results shows significant higher expression of Egfl7 in prostate cancer cells compared to normal prostate tissues.…”

Section: Prostate Cancer Endothelium-associated Antigensmentioning

confidence: 99%

Prostate cancer relevant antigens and enzymes for targeted drug delivery

Barve

Jin

Cheng

2014

Journal of Controlled Release

View full text Add to dashboard Cite

Chemotherapy is one of the most widely used approaches in combating advanced prostate cancer, but its therapeutic efficacy is usually insufficient due to lack of specificity and associated toxicity. Lack of targeted delivery to prostate cancer cells is also the primary obstacles in achieving feasible therapeutic effect of other promising agents including peptide, protein, and nucleic acid. Consequently, there remains a critical need for strategies to increase the selectivity of anti-prostate cancer agents. This review will focus on various prostate cancer-specific antigens and enzymes that could be exploited for prostate cancer targeted drug delivery. Among various targeting strategies, active targeting is the most advanced approach to specifically deliver drugs to their designated cancer cells. In this approach, drug carriers are modified with targeting ligands that can specifically bind to prostate cancer-specific antigens. Moreover, there are several specific enzymes in the tumor microenvironment of prostate cancer that can be exploited for stimulus-responsive drug delivery systems. These systems can specifically release the active drug in the tumor microenvironment of prostate cancer, leading to enhanced tumor penetration efficiency.

show abstract

Expression of Egfl7 correlates with low-grade invasive lesions in human breast cancer

Cited by 20 publications

References 20 publications

Novel Expression of EGFL7 in Osteosarcoma and Sensitivity to Cisplatin

Novel Expression of EGFL7 in Osteosarcoma and Sensitivity to Cisplatin

Activation of EGFL7 within High Grade Ovarian Serous Carcinoma is Associated with Lower Tumor Infiltrating CD4+ and CD8+ Lymphocytes

Prostate cancer relevant antigens and enzymes for targeted drug delivery

Contact Info

Product

Resources

About